NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-NS-21-016 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.
Funding Opportunity PAR-21-163 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Notice NOT-MH-21-190 from the NIH Guide for Grants and Contracts
Notice NOT-NR-21-002 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-014 from the NIH Guide for Grants and Contracts
Notice NOT-NR-21-001 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-032 from the NIH Guide for Grants and Contracts
Notice NOT-HD-20-032 from the NIH Guide for Grants and Contracts
BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-MH-21-135 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-19-147. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope.
Funding Opportunity RFA-MH-21-130 from the NIH Guide for Grants and Contracts. This is a reissue of RFA-MH-20-120. This FOA invites applications that will conduct secondary analysis or data mining of existing data relevant to the BRAIN Initiative goal of understanding brain circuits. The FOA also invites applications that seek to prepare and submit existing data that are highly relevant to the BRAIN Initiative into one of the BRAIN Initiative data archives. Applications can propose to generate or test new hypotheses which would not be possible in studies of single experiments, single technologies or single laboratories, or were beyond the scope of the original studies. Applications that propose to reanalyze existing data sets using new tools or approaches are also welcome. The proposed research may involve innovative analyses of existing data or novel combination or integration of existing data sets to address new aims or explore new questions.
Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-OD-21-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institutes (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.
Funding Opportunity RFA-OD-21-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority.
Funding Opportunity PAS-21-150 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.
Funding Opportunity RFA-MH-21-170 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (FOA) invites applications to continue the activities of the National NeuroAIDS Tissue Repository (NNTC), a data coordination center for the CHARTER cohort (a cohort of individuals living with HIV on Antiretroviral therapy). CHARTER research sites and DCC will continue to collect and provide research data as well as research specimens to interested investigators to address high priority research areas in NeuroHIV.
Notice NOT-TR-21-023 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-025 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-020 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-071 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-191 from the NIH Guide for Grants and Contracts. Nearly 40,000 people in the U.S. die from firearm-related deaths each year, primarily from suicide (60%) or homicide (37%), and many more have experienced non-fatal firearm injuries, both intentional and nonintentional. The Joint Explanatory Statement accompanying the Consolidated Appropriations Act, 2021 (Public Law 116-260) included funding for the NIH to conduct research on firearm injury and mortality prevention and recommended that NIH take a comprehensive approach to studying the underlying causes and evidence-based methods of prevention of firearm injury, including crime prevention. Within the legislative mandates and limitations of NIH funding (NOT-OD-21-058, NOT-OD-21-056), the NIH encourages research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including both victims and perpetrators), the development and piloting of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.
Funding Opportunity PAR-21-192 from the NIH Guide for Grants and Contracts. Nearly 40,000 people in the U.S. die from firearm-related deaths each year, primarily from suicide (60%) or homicide (37%), and many more have experienced non-fatal firearm injuries, both intentional and nonintentional. The Joint Explanatory Statement accompanying the Consolidated Appropriations Act, 2021 (Public Law 116-260) included funding for the NIH to conduct research on firearm injury and mortality prevention and recommended that NIH take a comprehensive approach to studying the underlying causes and evidence-based methods of prevention of firearm injury, including crime prevention. Within the legislative mandates and limitations of NIH funding (NOT-OD-21-058, NOT-OD-21-056), the NIH encourages research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including both victims and perpetrators), the development and evaluation of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.